Merck, Inc.
🇵🇭Philippines
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-07-01
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT00040547
Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2002-06-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 316
- Registration Number
- NCT00040131
PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-06-14
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2333
- Registration Number
- NCT00039871
Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry Eye
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 222
- Registration Number
- NCT00037661
Phase III PEG-Intron in HIV-infected Patients (Study P00738)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 49
- Registration Number
- NCT00035360
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 468
- Registration Number
- NCT00035009
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT00035048
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 900
- Registration Number
- NCT00034983
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 495
- Registration Number
- NCT00034944
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 584
- Registration Number
- NCT00035295
© Copyright 2024. All Rights Reserved by MedPath